BiotechTube

Nivolumab + Gemcitabine + Cisplatin

Phase 3Active
0 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Urinary Bladder Neoplasms

Conditions

Urinary Bladder Neoplasms, Muscle-Invasive Bladder Cancer

Trial Timeline

Nov 6, 2018 → Dec 30, 2027

NCT ID
NCT03661320

About Nivolumab + Gemcitabine + Cisplatin

Nivolumab + Gemcitabine + Cisplatin is a phase 3 stage product being developed by Ono Pharmaceutical for Urinary Bladder Neoplasms. The current trial status is active. This product is registered under clinical trial identifier NCT03661320. Target conditions include Urinary Bladder Neoplasms, Muscle-Invasive Bladder Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Urinary Bladder Neoplasms were approved

Approved (20) Terminated (1) Active (0)
✅Levofloxacin + LevofloxacinDr. Reddy's LaboratoriesApproved
✅solifenacin succinate + tamsulosin + placeboAstellas PharmaApproved
✅SolifenacinAstellas PharmaApproved
✅Levofloxacin + Solifenacin succinate + Placebo (for Solifenacin succinate)Astellas PharmaApproved
✅Tamsulosin + SolifenacinAstellas PharmaApproved
✅Alpha blocker + placebo + solifenacinAstellas PharmaApproved
✅solifenacin succinate + PlaceboAstellas PharmaApproved

Hype Score Breakdown

Clinical
17
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03661320Phase 3Active

Competing Products

20 competing products in Urinary Bladder Neoplasms

See all competitors
ProductCompanyStageHype Score
Levofloxacin + LevofloxacinDr. Reddy's LaboratoriesApproved
36
Duloxetine + placeboEli LillyPhase 2
35
DuloxetineEli LillyPhase 2
35
Enfortumab vedotinAstellas PharmaPhase 1
21
solifenacin succinate + tamsulosin + placeboAstellas PharmaApproved
43
solifenacin succinate + tamsulosin hydrochloride + Placebo to solifenacin + Placebo to tamsulosinAstellas PharmaPhase 2
35
SolifenacinAstellas PharmaApproved
43
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
40
Levofloxacin + Solifenacin succinate + Placebo (for Solifenacin succinate)Astellas PharmaApproved
39
solifenacin succinateAstellas PharmaPhase 3
40
SolifenacinAstellas PharmaPre-clinical
26
SolifenacinAstellas PharmaPre-clinical
26
TamuslosinAstellas PharmaPhase 3
40
Tamsulosin + SolifenacinAstellas PharmaApproved
43
Alpha blocker + placebo + solifenacinAstellas PharmaApproved
43
mirabegron 25 mg + mirabegron 50 mg + solifenacin 5 mg + solifenacin 10 mg + mirabegron 25 mg matching placebo + mirabegron 50 mg matching placebo + solifenacin 5 mg matching placebo + solifenacin 10 mg matching placeboAstellas PharmaPhase 3
40
solifenacin succinate + tolterodineAstellas PharmaPhase 3
40
TamusulosinAstellas PharmaPhase 3
40
SolifenacinAstellas PharmaPre-clinical
26
Solifenacin succinate + TolterodineAstellas PharmaPhase 3
40